πŸ‡ΊπŸ‡Έ FDA
Patent

US 12280055

Combination therapies

granted A61KA61K31/502A61K31/5025

Quick answer

US patent 12280055 (Combination therapies) held by Mirati Therapeutics, Inc. expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Mirati Therapeutics, Inc.
Grant date
Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K31/502, A61K31/5025, A61K31/506, A61K31/519